Loading
IARC estimates 31,204 new cancer cases and 15,711 cancer deaths in Ecuador in 2024; the commonest new cancers are prostate, breast and stomach. This page is assembled automatically from OnCo's data: 1 trial with a site there, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Prostate | 4,072 | 41.8 | Prostate cancer |
| Breast | 3,614 | 33.5 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Stomach | 3,100 | 13.9 | Gastric & gastro-oesophageal junction cancer |
| Colorectum | 2,543 | 11.6 | Colorectal cancer |
| Cervix uteri | 1,967 | 17.9 | Cervical cancer |
| Thyroid | 1,921 | 8.8 | Thyroid cancer |
| Non-Hodgkin lymphoma | 1,211 | 5.7 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Liver and intrahepatic bile ducts | 1,155 | 5.2 | Hepatocellular carcinoma |
| Trachea, bronchus and lung | 1,118 | 5.0 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Leukaemia | 1,047 | 5.3 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Stomach | 2,281 | 10.3 | Gastric & gastro-oesophageal junction cancer |
| Prostate | 1,518 | 15.5 | Prostate cancer |
| Colorectum | 1,320 | 6.0 | Colorectal cancer |
| Liver and intrahepatic bile ducts | 1,077 | 4.9 | Hepatocellular carcinoma |
| Breast | 994 | 9.2 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Cervix uteri | 991 | 9.0 | Cervical cancer |
| Trachea, bronchus and lung | 988 | 4.5 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Leukaemia | 728 | 3.7 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Pancreas | 711 | 3.3 | Pancreatic ductal adenocarcinoma |
| Non-Hodgkin lymphoma | 572 | 2.7 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
CLEOPATRA NCT00567190 | Phase 3 | Completed | Genentech, Inc. | 322 | 2019-12-13 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Ecuador, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Ecuador is open is on the registry page, under Contacts and Locations.
OnCo holds no institution, company or person in Ecuador.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Ecuador is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
A deep dive for Ecuador is ranked 45 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.